文献速递胸部肿瘤乳腺癌消化系统肿瘤

SHR-A2102(靶向Nectin-4的抗体药物偶联物)治疗经治晚期实体瘤的多中心单臂1期试验

SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial.
PubMed 文献 · Lancet Oncol · 2026-01-01

SHR-A2102是一种靶向Nectin-4的抗体药物偶联物,通过可裂解连接子偶联拓扑异构酶I抑制剂载荷。该多中心单臂1期试验在中国39家医院纳入395例经治晚期实体瘤患者,评估其安全性、初步活性和药代动力学。结果显示安全性特征与载荷一致,多种瘤种中观察到积极活性,未达到最大耐受剂量。

要点

  • 剂量扩展阶段选定6 mg/kg和8 mg/kg,最大耐受剂量未达到。
  • 3-4级治疗相关不良事件发生率54%,最常见为中性粒细胞计数降低(30%)。
  • 治疗相关死亡2例(<1%),为肺栓塞和肺炎。

核心结论

  • SHR-A2102的安全性特征与其拓扑异构酶I抑制剂载荷一致,在既往接受过抗肿瘤治疗的多种晚期实体瘤患者中显示出积极活性。
  • 在多种肿瘤类型中确定了一系列有效剂量,多项评估SHR-A2102单药或联合治疗的试验正在进行中。

研究设计与样本

  • 多中心、单臂1期试验,在中国39家医院开展,包括剂量递增(贝叶斯最优区间设计)、药代动力学扩展和疗效扩展阶段。
  • 纳入年龄≥18岁、不可切除局部晚期或转移性实体瘤、经治后进展或不耐受或无标准治疗、ECOG体能状态评分0或1的患者,共395例接受治疗。
  • SHR-A2102静脉给药,剂量2-10 mg/kg,每3周一次;主要终点为安全性、剂量限制性毒性、最大耐受剂量和推荐2期剂量。

主要发现

  • 2023年4月17日至2025年2月20日共纳入395例患者,中位年龄59岁(IQR 53-66),男性239例(61%),女性156例(39%),全部为中国患者。
  • 瘤种包括非小细胞肺癌197例、激素受体阳性HER2阴性乳腺癌32例、三阴性乳腺癌36例、食管鳞癌77例、头颈部鳞癌26例及其他实体瘤27例。
  • 3-4级治疗相关不良事件发生于212例(54%)患者,最常见为中性粒细胞计数降低(118例[30%])、白细胞计数降低(75例[19%])和贫血(69例[17%])。
  • 治疗相关严重不良事件发生于98例(25%)患者,最常见为肺炎(21例[5%]);治疗相关死亡2例(<1%),分别为肺栓塞和肺炎。

临床怎么用

  • SHR-A2102在经治晚期实体瘤中显示出可控的安全性和初步抗肿瘤活性,支持进一步开展单药及联合治疗研究。
  • 临床应用中需重点监测血液学毒性(中性粒细胞减少、白细胞减少、贫血)及肺炎等严重不良事件。

局限性

  • 单臂设计,无随机对照,初步活性需后续试验验证。
  • 全部为中国患者,结果外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: SHR-A2102 is a new antibody-drug conjugate consisting of a fully human nectin-4-directed monoclonal antibody bound to a topoisomerase I inhibitor payload via a cleavable linker. We did a phase 1 trial to evaluate the safety, preliminary activity, and pharmacokinetics of SHR-A2102 in advanced solid tumours. METHODS: This multicentre, single-arm, phase 1 trial was done at 39 hospitals in China and included dose-escalation (Bayesian Optimal Interval design), pharmacokinetic-expansion, and efficacy-expansion stages. Eligible patients were aged at least 18 years, had unresectable, locally advanced or metastatic solid tumours that had progressed after, were intolerant to, or had no available standard therapy, and had an Eastern Cooperative Oncology Group performance status score of 0 or 1. Patients received SHR-A2102 intravenously at doses of 2-10 mg/kg once every 3 weeks. The primary endpoints were safety, dose-limiting toxicity, maximum tolerated dose, and recommended phase 2 dose. All patients who received at least one dose of SHR-A2102 were included in the safety and activity analyses. This trial is registered at ClinicalTrials.gov (NCT05701709) and is ongoing. FINDINGS: Between April 17, 2023 and Feb 20, 2025, 395 patients (median age 59 years [IQR 53-66]; 239 [61%] male and 156 [39%] female; 395 [100%] Chinese) were enrolled and treated across study stages, including 197 with non-small cell lung cancer, 32 with hormone receptor-positive, HER2-negative breast cancer, 36 with triple-negative breast cancer, 77 with oesophageal squamous cell carcinoma, 26 with head-and-neck squamous-cell carcinoma, and 27 with other solid tumours. As of data cutoff (June 20, 2025), the median follow-up was 7·2 months (IQR 4·7-9·7). Based on data from the dose-escalation stage, 6 mg/kg (n=10) and 8 mg/kg (n=11) were selected for pharmacokinetic expansion. During dose escalation, one dose-limiting toxicity was reported at 10 mg/kg (grade 4 decreased platelet count); maximum tolerated dose was not reached. Grade 3-4 treatment-related adverse events were reported in 212 (54%) of 395 patients, with the most common being decreased neutrophil count (118 [30%]), decreased white-blood-cell count (75 [19%]), and anaemia (69 [17%]). Treatment-related serious adverse events were reported in 98 (25%) patients with the most common being pneumonia (21 [5%]). Treatment-related deaths occurred in two (<1%) patients (pulmonary embolism and pneumonia). INTERPRETATION: SHR-A2102 demonstrated a safety profile consistent with its topoisomerase I inhibitor payload and showed promising activity in patients with various advanced solid tumours who had previously received anti-cancer treatment. A range of active dose was identified in various tumour types. Several trials are ongoing to evaluate SHR-A2102, either as monotherapy or in combination, in advanced solid tumours. FUNDING: Jiangsu Hengrui Pharmaceuticals.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Zhong R, Hong H, Yan M, et al. SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial. Lancet Oncol. 2026. PMID: 42636836. doi:10.1016/S1470-2045(26)00238-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。